Stereotaxis (STXS) 10-K 8 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Feb. 29, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-36159
Entity Registrant Name	STEREOTAXIS, INC.
Entity Central Index Key	0001289340
Entity Tax Identification Number	94-3120386
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	710 North Tucker Boulevard
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	St. Louis
Entity Address, State or Province	MO
Entity Address, Postal Zip Code	63101
City Area Code	(314)
Local Phone Number	678-6100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	STXS
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 100.9
Entity Common Stock, Shares Outstanding		82,128,762
Documents Incorporated by Reference [Text Block]	Portions of the Proxy Statement for the registrant’s 2024 Annual Meeting of Shareholders are incorporated by reference in Part III, Items 10, 11, 12, 13 and 14.
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	St. Louis, Missouri

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,818	$ 8,586
Restricted cash - current	525	525
Short-term investments		19,844
Accounts receivable, net of allowance of $672 and $235 at 2023 and 2022, respectively	3,822	5,090
Inventories, net	8,426	7,876
Prepaid expenses and other current assets	676	1,325
Total current assets	33,267	43,246
Property and equipment, net	3,304	3,831
Restricted cash	219	744
Operating lease right-of-use assets	4,982	5,384
Prepaid and other non-current assets	137	208
Total assets	41,909	53,413
Current liabilities:
Accounts payable	3,190	3,270
Accrued liabilities	2,972	3,306
Deferred revenue	6,657	7,342
Current portion of operating lease liabilities	428	373
Total current liabilities	13,247	14,291
Long-term deferred revenue	1,637	1,654
Operating lease liabilities	5,062	5,488
Other liabilities	43	51
Total liabilities	19,989	21,484
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 22,358 and 22,383 shares outstanding at 2023 and 2022, respectively	5,577	5,583
Stockholders’ equity:
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2022		6
Common stock, par value $0.001; 300,000,000 shares authorized, 80,949,697 and 74,874,459 shares issued at 2023 and 2022, respectively	81	75
Additional paid in capital	554,148	543,438
Treasury stock, 4,015 shares at 2023 and 2022	(206)	(206)
Accumulated deficit	(537,680)	(516,967)
Total stockholders’ equity	16,343	26,346
Total liabilities and stockholders’ equity	$ 41,909	$ 53,413

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 672	$ 235
Series A convertible preferred stock, par value	$ 0.001	$ 0.001
Series A convertible preferred stock, shares outstanding	22,358	22,383
Series B convertible preferred stock, par value	$ 0.001	$ 0.001
Series B convertible preferred stock, shares authorized	10,000,000	10,000,000
Series B convertible preferred stock, shares outstanding		5,610,121
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	80,949,697	74,874,459
Treasury stock, shares	4,015	4,015

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 26,771	$ 28,147
Cost of revenue:
Total cost of revenue	11,911	9,677
Gross margin	14,860	18,470
Operating expenses:
Research and development	10,273	10,558
Sales and marketing	12,376	12,325
General and administrative	14,050	14,363
Total operating expenses	36,699	37,246
Operating loss	(21,839)	(18,776)
Other income	30
Interest income, net	1,096	484
Net loss	(20,713)	(18,292)
Cumulative dividend on convertible preferred stock	(1,343)	(1,343)
Net loss attributable to common stockholders	$ (22,056)	$ (19,635)
Net loss per share attributable to common stockholders:
Basic	$ (0.27)	$ (0.26)
Diluted	$ (0.27)	$ (0.26)
Weighted average number of common shares and equivalents:
Basic	80,702,358	76,061,183
Diluted	80,702,358	76,061,183
Systems [Member]
Revenue:
Total revenue	$ 8,739	$ 6,845
Cost of revenue:
Total cost of revenue	8,058	5,802
Disposables Service and Accessories [Member]
Revenue:
Total revenue	18,032	21,302
Cost of revenue:
Total cost of revenue	$ 3,853	$ 3,875

Statements of Convertible Prefe

Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Convertible preferred stock series A [Member]	Convertible preferred stock series B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 5,584	$ 6	$ 75	$ 532,641	$ (206)	$ (498,675)	$ 33,841
Balance, shares at Dec. 31, 2021	22,387	5,610,121	74,618,240
Stock issued for the exercise of stock options and stock appreciation rights				102			102
Stock issued for the exercise of stock options and stock appreciation rights, shares			92,377
Stock-based compensation				10,576			10,576
Stock-based compensation, shares			110,726
Components of net loss						(18,292)	(18,292)
Employee stock purchase plan				118			118
Employee stock purchase plan, shares			44,783
Preferred stock conversion	$ (1)			1			1
Preferred stock conversion, shares	(4)		8,333
Balance at Dec. 31, 2022	$ 5,583	$ 6	$ 75	543,438	(206)	(516,967)	26,346
Balance, shares at Dec. 31, 2022	22,383	5,610,121	74,874,459
Stock issued for the exercise of stock options and stock appreciation rights				(15)			(15)
Stock issued for the exercise of stock options and stock appreciation rights, shares			34,125
Stock-based compensation				10,623			10,623
Stock-based compensation, shares			319,019
Components of net loss						(20,713)	(20,713)
Employee stock purchase plan				96			96
Employee stock purchase plan, shares			56,966
Preferred stock conversion	$ (6)	$ (6)	$ 6	6			6
Preferred stock conversion, shares	(25)	(5,610,121)	5,665,128
Balance at Dec. 31, 2023	$ 5,577		$ 81	$ 554,148	$ (206)	$ (537,680)	$ 16,343
Balance, shares at Dec. 31, 2023	22,358		80,949,697

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (20,713)	$ (18,292)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	595	429
Non-cash lease expense	31	103
Stock-based compensation	10,623	10,576
Accretion and short-term investment discount	(287)	(128)
Changes in operating assets and liabilities:
Accounts receivable	1,268	316
Inventories	(550)	(2,906)
Prepaid expenses and other current assets	649	1,031
Other assets	71	70
Accounts payable	218	(169)
Accrued liabilities	(334)	(267)
Deferred revenue	(702)	989
Other liabilities	(8)	(167)
Net cash used in operating activities	(9,139)	(8,415)
Cash flows from investing activities
Purchase of property and equipment	(366)	(2,378)
Purchases of short-term investments		(19,716)
Proceeds from maturity of short-term investments	20,131
Net cash provided by (used in) investing activities	19,765	(22,094)
Cash flows from financing activities
Proceeds from issuance of stock, net of issuance costs	81	220
Net cash provided by financing activities	81	220
Net increase (decrease) in cash, cash equivalents, and restricted cash	10,707	(30,289)
Cash, cash equivalents, and restricted cash at beginning of period	9,855	40,144
Cash, cash equivalents, and restricted cash at end of period	20,562	9,855
Supplemental disclosure of cash flow information:
Purchase of property and equipment included in accounts payable		313
Reconciliation of cash, cash equivalents, and restricted cash to balance sheet as of December 31st:
Cash and cash equivalents	19,818	8,586
Restricted cash - current	525	525
Restricted cash	219	744
Total cash, cash equivalents, and restricted cash	$ 20,562	$ 9,855

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Stereotaxis designs, manufactures and markets robotic systems, instruments and information systems for the interventional laboratory. Our proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Direct control of the tip of an interventional device, in contrast to all manual hand-held devices that are controlled from their handle, can improve the precision, stability, reach and safety of these devices during procedures. Our primary clinical focus has been electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias. Cardiac ablation has become a well-accepted therapy for arrhythmias and a multi-billion-dollar medical device market with expectations for substantial long-term growth. We have shared our aspiration and a product strategy to expand the clinical focus of our technology to several additional endovascular indications including coronary, neuro, and peripheral interventions. There is substantial real-world evidence and clinical literature for Robotic Magnetic Navigation in electrophysiology. Hundreds of electrophysiologists at over one hundred hospitals globally have treated over 100,000 arrhythmia patients with our robotic technology. Clinical use of our technology has been documented in over 400 clinical publications. Robotic Magnetic Navigation is designed to enable physicians to complete more complex interventional procedures with greater success and safety by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied computer-controlled magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation. The more flexible atraumatic design of catheters driven using magnetic fields may reduce the risk of patient harm and other adverse events. Performing the procedure from a control cockpit enables physicians to complete procedures in a safe location protected from x-ray exposure, with greater ergonomics, and improved efficiency. We believe these benefits can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure. Our primary products include the Genesis RMN Odyssey The Genesis RMN System The Odyssey Solution Odyssey Cinema, We have arrangements with fluoroscopy system manufacturers to provide such systems in a bundled purchase offer for hospitals establishing robotic interventional operating rooms. These are single-plane, full-power x-ray systems and include the c-arm and powered table. The combination of RMN Systems with our partnered x-ray systems reduces the cost of acquisition, the ongoing cost of ownership, and the complexity of installation of a robotic electrophysiology practice. We promote our full suite of products in a typical hospital implementation, subject to regulatory approvals or clearances. This implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and ongoing software updates. In hospitals where our full suite of products has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. We have received regulatory clearances and approvals necessary for us to market the Genesis RMN Niobe Odyssey Cardiodrive Vdrive Vdrive Duo V-CAS We have strategic relationships with technology leaders and innovators in the global interventional market. Through these strategic relationships we provide compatibility between our robotic magnetic navigation system, x-ray systems, and digital imaging and 3D catheter location sensing technology, as well as disposable interventional devices. The maintenance of these strategic relationships, or the establishment of equivalent alternatives, is critical to our commercialization efforts. There are no guarantees that any existing strategic relationships will continue, and efforts are ongoing to ensure the availability of compatible systems and devices and/or equivalent alternatives. We cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. Our investments may include, at any time, a diversified portfolio of cash equivalents and short-term and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company closely monitors events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, including Silicon Valley Bank. On March 10, 2023, Silicon Valley Bank (“SVB”), where the Company maintained accounts with a cash balance of less than 6 Cash and Cash Equivalents Cash and cash equivalents include cash on hand, money market instruments, and other highly liquid investments with original maturities of three months or less from the date of purchase. Restricted Cash Restricted cash primarily consists of cash that the Company is obligated to maintain in accordance with contractual obligations. Investments Our investments may include, at any time, a diversified portfolio of cash equivalents and short-and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. As of December 31, 2023, the Company had no Amortized cost of U.S. treasury securities and marketable debt securities are based on the Company’s purchase price adjusted for accrual of discount, or amortization of premium, and recognition of impairment charges, if any. The amortized cost of securities the Company purchases at a discount or premium will equal the face or par value at maturity or the call date, if applicable. Stated interest on investments is reported as income when earned and is adjusted for amortization or accretion of any premium or discount. Accrued interest receivable on investments, included in other current assets was less than $ 0.1 Effective January 1, 2023, the Company reports held to maturity investments net of an allowance for expected credit losses in accordance with Accounting Standards Codification Topic 326, Financial Instruments – Credit Losses (“ASC 326”). The adoption of ASC 326 had no material impact on the Company’s financial results for any prior periods, therefore no cumulative adjustment to beginning retained earnings was recorded. The Company segments its portfolio based on the underlying risk profiles of the securities and has a zero-loss expectation for U.S. treasury and U.S. government agency securities. The Company regularly reviews the securities using the probability of default method and analyzes the unrealized loss positions and evaluates the current expected credit loss by considering factors such as credit ratings, issuer-specific factors, current economic conditions, and reasonable and supportable forecasts. The Company did not have any material expected credit losses on investments or material expected credit losses on accrued interest related to investments during the years ended December 31, 2023, or December 31, 2022. Fair Value Measurements Financial instruments consist of cash and cash equivalents, restricted cash, investments, accounts receivable, and accounts payable. The Company measures certain financial assets and liabilities at fair value on a recurring basis. General accounting principles for fair value measurement establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below: Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market. Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market. As of December 31, 2023, financial assets classified as Level 2 consisted of money market funds. As of December 31, 2022, financial assets classified as Level 2 consisted of money market funds, U.S. treasury securities and corporate debt securities. Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts, net of allowances for expected credit losses. Credit is granted on a limited basis, with balances due generally within 30 days of billing. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Effective January 1, 2023, the Company reports accounts receivable and contract assets net of an allowance for expected credit losses in accordance with Accounting Standards Codification Topic 326, Financial Instruments – Credit Losses (“ASC 326”). The adoption of ASC 326 had no material impact on the Company’s financial results for any prior periods, therefore no cumulative adjustment to beginning retained earnings was recorded. The provision for credit loss is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. We assess collectability by reviewing the accounts receivable aging schedule on an aggregated basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectability issues. Amounts deemed uncollectible are recorded as an allowance for expected credit losses. Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or net realizable value. The Company periodically reviews its physical inventory and provides a reserve upon identification of potential excess or obsolete items. Excess manufacturing overhead costs attributable to idle facility expenses or abnormally low production volumes are excluded from inventory and recorded as an expense in the period incurred. Property and Equipment Property and equipment consist primarily of leasehold improvements, construction in process, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 3 inputs. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates. Revenue and Costs of Revenue Revenue Recognition The Company accounts for revenue in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue from Contracts with Customers We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale of various devices as provided by co-development and co-placement arrangements, and from revenue including ongoing software updates and service contracts. We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities. For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. For arrangements with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates if necessary. Our revenue recognition policy affects the following revenue streams in our business as follows: Systems: Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation, service-type warranty, and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from service-type warranties and the implied obligation to deliver software enhancements if and when available is included in Other Recurring Revenue and is recognized ratably typically over the first year following installation of the system as the customer receives the service-type warranty and right to software updates throughout the period. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year service-type warranty or a one-year assurance-type warranty. Warranty costs for assurance-type warranty arrangements were approximately $ 0.5 0.1 33 24 Disposables: Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance-type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 24 28 Royalty: The Company receives royalties on the sale of various devices as provided by co-development and co-placement arrangements with various manufacturers. The Company was entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters, during the term of the agreement, which expired December 31, 2022. Royalty revenue from co-development and co-placement arrangements represented less than 1 7 years e Other Recurring Revenue: Other recurring revenue includes revenue from product maintenance plans, service-type warranties, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for a specified period, typically one year following installation of our systems. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 43 41 The following table summarizes the Company’s revenue for systems and disposables, service and accessories for the years ended December 31, 2023 and 2022 (in thousands): Schedule of Revenue Disaggregated by Type 2023 2022 Year Ended December 31, 2023 2022 Systems $ 8,739 $ 6,845 Disposables, service and accessories 18,032 21,302 Total revenue $ 26,771 $ 28,147 Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company’s systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $ 14.7 The following information summarizes the Company’s contract assets and liabilities (in thousands): Summary of Contract Assets and Liabilities December 31, 2023 December 31, 2022 Contract Assets - unbilled receivables $ 72 $ 539 Customer deposits $ 2,105 $ 2,339 Product shipped, revenue deferred 1,413 1,389 Deferred service and license fees 4,776 5,268 Total deferred revenue $ 8,294 $ 8,996 Less: Long-term deferred revenue (1,637 ) (1,654 ) Total current deferred revenue $ 6,657 $ 7,342 The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Customer deposits primarily relate to future system sales but can also include deposits on disposable sales. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2023 and 2022, that was included in the deferred revenue balance at the beginning of each reporting period was $ 6.1 5.9 The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets in the Company’s balance sheets $ 0.1 0.2 Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, initial training costs and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Leasing Arrangements A lease is defined as a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company accounts for leases in accordance with Accounting Standards Update No. 2016-02 “Leases” (Topic 842) and all subsequent ASUs that modified Topic 842 (“ASC 842”). The Company determines if an arrangement contains a lease at inception. The Company leases its facilities under operating leases. In accordance with ASC 842, operating lease agreements are recognized on the balance sheet as a right-of-use (“ROU”) asset and a corresponding lease liability. These leases generally do not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. Further, the leases do not contain contingent rent provisions. Many of our leases include both lease (i.e., fixed payments including rent, taxes, and insurance costs) and non-lease components (i.e., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. The Company’s lease agreements often include one or more options to renew at the Company’s discretion. If at lease inception, the Company considers the exercising of a renewal option to be reasonably certain, the Company will include the extended term in the calculation of the ROU asset and lease liability. The Company elected not to include short-term leases (i.e., leases with initial terms of twelve months or less) on the balance sheet. The calculated amounts of the ROU assets and lease liabilities are impacted by the length of the lease term and the discount rate used to calculate the present value of the minimum lease payments. ASC 842 requires the use of the discount rate implicit in the lease whenever this rate is readily determinable. As this rate is rarely determinable, the Company utilizes its incremental borrowing rate at lease inception. Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables as of December 31, 2023 or 2022, under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned. Stock-Based Compensation The Company accounts for its grants of stock options, non-qualified stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the stock-based compensation at the grant date and the recognition of the related expense over the period in which the stock-based compensation vests. For time-based awards, the Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The weighted average assumptions and fair value for options granted during the year ended December 31, 2023, were 1) expected dividend rate of 0 76 6.25 For market-based awards, stock-based compensation expense is recognized over the minimum service period regardless of whether or not the market target is probable of being achieved. The fair value of such awards is estimated on the grant date using Monte Carlo simulations. Shares purchased by employees under the 2022 Employee Stock Purchase Plan are considered to be non-compensatory. Net Loss per Common Share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our convertible preferred stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our convertible preferred stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our convertible preferred stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2023, the Company had 3,650,115 3.93 49,375,135 1,502,131 Income Taxes In accordance with general accounting principles for income taxes , Product Warranty Provisions The Company’s standard policy is to warrant all products against defects in material or workmanship for one year following sale or installation. Contracts related to the sale of systems typically contain a service-type warranty which is accounted for as a separate performance obligation in ASC 606, Revenue from Contracts with Customers Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. Concentrations of Risk No single customer accounted for more than 10 10 Recently Issued Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires enhanced income tax disclosures, primarily related to the effective tax rate reconciliation and income taxes paid. The Company does not expect a significant impact on its income tax disclosures upon adoption of the ASU which will be effective in the Company’s year ending December 31, 2025.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2023
Investments, All Other Investments [Abstract]
Financial Instruments	3. Financial Instruments The following table summarizes the Company’s cash and held to maturity securities’ amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category reported as cash and cash equivalents, restricted cash and investments as of December 31, 2023 and 2022: Schedule of Cash and Cash Equivalents, Restricted Cash and Investments December 31, 2023 Valuation Balance Sheet Classification (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Restricted Cash- current Short-term Investments Restricted Cash Cash $ 2,122 $ - $ - $ 2,122 $ 2,122 $ - $ - $ - Level 2 Money market funds 18,440 - - 18,440 17,696 525 - 219 US treasury securities - - - - - - - - Corporate debt securities - - - - - - - - Subtotal 18,440 - - 18,440 17,696 525 - 219 Total assets measured at fair value $ 20,562 $ - $ - $ 20,562 $ 19,818 $ 525 $ - $ 219 December 31, 2022 Valuation Balance Sheet Classification (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Restricted Cash- current Short-term Investments Restricted Cash Cash $ 3,258 $ - $ - $ 3,258 $ 3,258 $ - $ - $ - Level 2 Money market funds 1,615 - - 1,615 346 525 - 744 US treasury securities 14,833 2 (2 ) 14,833 4,982 - 9,851 - Corporate debt securities 9,993 - (6 ) 9,987 - - 9,993 - Subtotal 26,441 2 (8 26,435 5,328 525 19,844 744 Total assets measured at fair value $ 29,699 $ 2 $ (8 ) $ 29,693 $ 8,586 $ 525 $ 19,844 $ 744 Interest income recorded for these cash and investments was $ 1.1 0.5 As of December 31, 2023 and 2022, the Company did not have any financial assets classified as Level 1 or Level 3 nor did the Company have financial liabilities valued at fair value on a recurring basis.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventory	4. Inventory Inventory consists of the following (in thousands): Schedule of Inventories December 31, 2023 December 31, 2022 Raw materials $ 5,918 $ 6,556 Work in process 1,034 530 Finished goods 3,413 2,697 Reserve for excess and obsolescence (1,939 ) (1,907 ) Total inventory $ 8,426 $ 7,876

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other assets consist of the following (in thousands): Schedule of Prepaid Expenses and Other Assets December 31, 2023 December 31, 2022 Prepaid expenses $ 181 $ 605 Prepaid commissions 110 187 Deposits 424 669 Other assets 98 72 Total prepaid expenses and other assets 813 1,533 Less: Noncurrent prepaid expenses and other assets (137 ) (208 ) Total current prepaid expenses and other assets $ 676 $ 1,325

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment consist of the following (in thousands): Schedule of Property and Equipment December 31, 2023 December 31, 2022 Equipment $ 4,269 $ 4,393 Leasehold improvements 2,911 2,692 Construction in process - 204 Gross property and equipment 7,180 7,289 Less: Accumulated depreciation (3,876 ) (3,458 ) Net property and equipment $ 3,304 $ 3,831 The Company retired approximately $ 0.2 0.1 1.2

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases
Leases	7. Leases On March 1, 2021, the Company entered into an office lease agreement (the “Lease”) with Globe Building Company (the “Landlord”), under which the Company leases executive office space and manufacturing facilities of approximately 43,100 ten years two five years 0.8 1.0 As of December 31, 2023, the weighted average discount rate for operating leases was 9 7.99 The following table represents lease costs and other lease information (in thousands): Schedule of Lease Costs and Other Lease Information 2023 2022 Year Ended December 31, 2023 2022 Operating lease cost $ 908 $ 909 Short-term lease cost 17 28 Total net lease cost $ 925 $ 937 Cash paid within operating cash flows $ 1,000 $ 1,126 Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our leased facilities and equipment which are paid based on actual costs incurred. Future minimum payments for operating leases with initial or remaining terms of one year or more as of December 31, 2023, were as follows (in thousands): Schedule of Future Minimum Operating Lease Payments December 31, 2023 2024 $ 898 2025 919 2026 935 2027 956 2028 976 2029 and thereafter 3,054 Total lease payments $ 7,738 Less: Interest (2,248 ) Present value of lease liabilities $ 5,490

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Liabilities	8. Accrued Liabilities Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities December 31, 2023 December 31, 2022 Accrued salaries, bonus, and benefits $ 1,222 $ 1,381 Accrued licenses and maintenance fees 484 484 Accrued warranties 107 163 Accrued professional services 138 129 Deferred contract obligation 1,045 1,045 Other 19 155 Total accrued liabilities 3,015 3,357 Less: Long term accrued liabilities (43 ) (51 ) Total current accrued liabilities $ 2,972 $ 3,306 Certain prior year amounts have been reclassified to conform to the 2023 presentation.

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders’ Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Convertible Preferred Stock and Stockholders’ Equity	9. Convertible Preferred Stock and Stockholders’ Equity The holders of common stock are entitled to one vote for each share held No Series B Convertible Preferred Stock On August 7, 2019, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors, whereby it, as part of a private placement, agreed to issue and sell to the investors 5,610,121 0.001 2.05 Series A Convertible Preferred Stock and Warrants In September 2016, the Company issued (i) 24,000 0.001 1,000 0.65 36,923,078 6 1,000 50 The SPA Warrants were modified on February 28, 2018 to allow for a reduction in the exercise price from $ 0.70 0.28 15,385 2021 CEO Performance Award Unit Grant On February 23, 2021, the Company`s Board of Directors, upon recommendation of the Compensation Committee, approved the grant of the CEO Performance Award to the Company’s Chief Executive Officer. The CEO Performance award is a 10 13,000,000 As detailed in the table below, the CEO Performance Award consists of ten vesting tranches. The first market capitalization milestone is $ 1.0 500 5.5 Summary of Performance Award And Market Capitalization Milestones Tranche # No. of Shares Subject to PSU Market Capitalization Milestones 1 1,000,000 $ 1,000,000,000 2 1,500,000 $ 1,500,000,000 3 1,500,000 $ 2,000,000,000 4 2,000,000 $ 2,500,000,000 5 1,000,000 $ 3,000,000,000 6 1,000,000 $ 3,500,000,000 7 1,000,000 $ 4,000,000,000 8 2,000,000 $ 4,500,000,000 9 1,000,000 $ 5,000,000,000 10 1,000,000 $ 5,500,000,000 Total: 13,000,000 Each tranche represents a portion of the PSUs covering the number of shares outlined in the table above. Each tranche vests upon (i) satisfaction of the market capitalization milestones and (ii) continued employment as CEO of the Company from the grant date through December 31, 2030. Absent an earlier termination, the PSUs will expire on December 31, 2030. If our CEO ceases employment as CEO of the Company for any reason including death, disability, termination for cause or without cause (as defined in the award agreement), or if he voluntary terminates after service as CEO for at least five years, the remaining service period will be waived and he will retain any PSUs that have vested through the date of termination. The Company received Shareholder approval at its annual meeting on May 20, 2021, for shares to be issued under the award. The market capitalization requirement is considered a market condition under FASB Accounting Standards Codification Topic 718 “Compensation – Stock Compensation” and is estimated on the grant date using Monte Carlo simulations. Recognition of stock-based compensation expense of all the tranches commenced on February 23, 2021, the date of grant, as the probability of meeting the ten market capitalization milestones is not considered in determining the timing of expense recognition. The expense will be recognized on an accelerated basis through 2030. Key assumptions for estimating the performance-based awards fair value at the date of grant included share price on grant date, volatility of the Company’s common stock price, risk free interest rate, and grant term. Total stock-based compensation recorded as operating expense for the CEO Performance Award was $ 7.1 37.0 44.1 Stock Award Plans The Company has various stock plans that permit the Company to provide incentives to employees, directors, and third-party consultants of the Company in the form of equity compensation. In February 2022, the Compensation Committee of the Board of Directors adopted the 2022 Stock Incentive Plan (the “Plan”) which was subsequently approved by the Company’s shareholders. This plan replaced the 2012 Stock Incentive Plan which expired on May 19, 2022 As of December 31, 2023, the Company had 2,690,393 The 2022 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and third-party consultants. Options granted under the 2022 Stock Incentive Plan expire no later than ten years 100 The vesting provisions of individual options may vary, but incentive stock options generally vest 25 three years Stock appreciation rights granted under the 2022 Stock Incentive Plan generally vest 25 three years ten years The fair value of the grants of restricted shares and units is determined based on the closing price of our stock on the date of grant. Restricted stock unit grants are time-based and generally vest over a period of four years except for grants to directors which are generally earned over a period of six months. As of December 31, 2023, the total compensation cost related to options, stock appreciation rights, and non-vested stock granted to employees and non-employees under the Company’s stock award plans but not yet recognized was approximately $ 3.2 four years A summary of the option and stock appreciation rights activity for the year ended December 31, 2023, is as follows: Summary of Option and Stock Appreciation Rights Activity Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share Outstanding, December 31, 2022 3,208,065 $ 0.74 9.87 $ 4.21 Granted 724,000 $ 1.51 2.57 $ 2.53 Exercised (33,929 ) $ 0.74 2.03 $ 1.09 Forfeited (248,021 ) $ 0.74 9.20 $ 3.96 Outstanding, December 31, 2023 3,650,115 $ 0.74 9.87 $ 3.93 As of December 31, 2023, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 6.88 3,650,115 2,364,166 3.93 6.0 A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows: Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price Year Ended December 31, 2023 Number of Weighted Weighted Weighted Options Average Exercise Options Average Average Currently Price Per Vested Range of Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Share $ 0.00 1.00 314,887 4.16 $ 0.74 314,887 $ 0.74 $ 1.01 2.00 80,516 8.52 $ 1.57 22,771 $ 1.47 $ 2.01 4.00 1,241,853 7.12 $ 2.33 600,481 $ 2.07 $ 4.01 10.00 2,012,859 7.08 $ 5.50 1,426,027 $ 5.45 3,650,115 6.88 $ 3.93 2,364,166 $ 3.93 The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options and stock appreciation rights that were in-the-money as of December 31, 2023. The intrinsic value of the options and stock appreciation rights outstanding as of December 31, 2023, was approximately $ 0.3 1.75 337,408 0.1 The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2022, was approximately $ 0.5 2.07 881,207 0.1 The weighted average grant date fair value of options granted during the years ended December 31, 2023 and 2022, was $ 2.53 4.49 A summary of the restricted stock unit activity for the year ended December 31, 2023, is as follows: Summary of Restricted Stock Unit Activity Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit Outstanding, December 31, 2022 1,208,739 $ 4.21 Granted 610,038 $ 1.97 Vested (316,646 ) $ 1.17 Outstanding, December 31, 2023 1,502,131 $ 3.94 The intrinsic value of restricted stock units outstanding as of December 31, 2023, was $ 2.6 1.75 2.5 2.07 0.6 2022 Employee Stock Purchase Plan In 2022, the Company adopted its 2022 Employee Stock Purchase Plan (“ESPP”). Eligible employees have the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees can purchase up to 15 25,000 95 107,688 The Company has reserved shares of common stock for conversion of convertible preferred stock, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows: Summary of Reserved Shares of Common Stock for Conversion December 31, December 31, 2023 2022 Series A Convertible Preferred Stock 54,704,831 45,023,612 Series B Convertible Preferred Stock - 5,610,121 Performance Share Unit Plan 13,000,000 13,000,000 Stock award plans 2,690,393 3,930,952 Employee Stock Purchase Plan 107,688 164,654 Reserved shares of common stock 70,502,912 67,729,339

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The provision for income taxes consists of the following (in thousands): Schedule of Provision For Income Taxes 2023 2022 Year Ended December 31, 2023 2022 Deferred: Federal $ (2,108 ) $ (1,990 ) State and local (773 ) (93 ) Total deferred income tax expense (benefit) (2,881 ) (2,083 ) Valuation allowance 2,881 2,083 Income tax benefit $ — $ — The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following: Schedule of Reconciliation of Federal Income Tax Rate 2023 2022 Year Ended December 31, 2023 2022 U.S. statutory income tax rate 21.0 % 21.0 % State and local taxes, net of federal tax benefit 1.7 % 1.1 % Stock compensation permanent differences between book and tax (7.2 )% (7.1 )% Other permanent differences between book and tax (2.4 )% (3.0 )% State rate adjustments 2.1 % (0.6 )% Other adjustments (1.3 )% - % Valuation allowance (13.9 )% (11.4 )% Effective income tax rate — % — % The stock compensation permanent difference relates to the February 3, 2021, Board approved grant of Performance Share Unit Award pursuant to the CEO Performance Share Unit Award Agreement (the “PSU Agreement” to David L. Fischel, the Company’s Chief Executive Officer. Total stock-based compensation attributed to the PSU Agreement was $ 7.1 The components of the deferred tax asset are as follows (in thousands): Schedule of Components of Deferred Tax Asset 2023 2022 Year Ended December 31, 2023 2022 Current accruals $ 1,041 $ 859 Operating lease liabilities 1,330 1,360 Deferred revenue 68 96 Depreciation and amortization 3,172 2,007 Deferred compensation 1,570 1,525 Net operating loss carryovers 29,118 27,629 Deferred tax assets 36,299 33,476 Valuation allowance (35,066 ) (32,184 ) Net deferred tax assets before deferred tax liabilities 1,233 1,292 Operating lease right-of-use assets (1,207 ) (1,249 ) Capitalized compensation costs (26 ) (43 ) Net deferred tax assets $ - $ - Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards. As a result of this review, it was determined that a large portion of the Company’s net operating loss carryovers would expire unused due to the limitation under IRC Section 382. The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations as reflected in the net operating loss carryovers in the table above. The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100 As of December 31, 2023, the Company had gross federal net operating loss carryforwards of approximately $ 127.4 213.7 98.8 expire between 2030 and 2037 40.2 expire at various dates between 2024 and 2042 if not utilized On December 31, 2020, Congress approved the Consolidations Appropriations Act, 2021, (the “Appropriations Act:), which was signed into law by the President on December 27, 2020. The Appropriations Act funded the federal government to the end of the fiscal 2020 year and provided COVID-19 economic relief. One of the business provisions included in the Appropriations Act is clarification of the income tax deductibility of business expenses that were paid for with the Payroll Protection Program funds. The Company will continue to monitor additional legislation related to COVID-19 and its impact on our operations. The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal net operating loss carryforward from the year ended December 31, 2003, forward, all tax years from 2003 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 As of December 31, 2023 and 2022, the Company had less than $ 0.1 0.1

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2023
Net loss per share attributable to common stockholders:
Net Loss per Share	11. Net Loss per Share The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations (in thousands): Schedule of Computation of Basic and Diluted Earnings Per Share 2023 2022 Year Ended December 31, 2023 2022 Net loss $ (20,713 ) $ (18,292 ) Cumulative dividend on convertible preferred stock (1,343 ) (1,343 ) Net loss attributable to common stockholders $ (22,056 ) $ (19,635 ) Weighted average number of common shares and equivalents: 80,702,358 76,061,183 Basic EPS $ (0.27 ) $ (0.26 ) Diluted EPS $ (0.27 ) $ (0.26 ) The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows: Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share December 31, 2023 2022 Shares issuable upon vesting/exercise of: Options to purchase common stock 3,650,115 3,208,065 Series A Convertible Preferred Stock and Accumulated Dividends 49,375,135 47,364,216 Series B Convertible Preferred Stock - 5,610,121 Restricted stock units 1,502,131 1,208,739 54,527,381 57,391,141

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Employee Benefit Plan	12. Employee Benefit Plan The Company offers employees the opportunity to participate in a 401(k) plan and matches employee contributions up to 3 0.3

Product Warranty Provisions

Product Warranty Provisions	12 Months Ended
	Dec. 31, 2023
Guarantees and Product Warranties [Abstract]
Product Warranty Provisions	13. Product Warranty Provisions The Company’s standard policy is to warrant all capital systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate. Accrued warranty, which is included in other accrued liabilities, consists of the following (in thousands): Schedule of Accrued Warranty December 31, 2023 December 31, 2022 Warranty accrual, beginning of the fiscal period $ 163 $ 242 Accrual adjustment for product warranty 547 113 Payments made (603 ) (192 ) Warranty accrual, end of the fiscal period $ 107 $ 163

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company. Subsequent to year end, security agreements have been executed under the provisions of the Uniform Commercial Code (“UCC”), and UCC financing statements have been filed by a vendor on underlying inventory for approximately $ 0.6 , In April 2021, the Company entered into a letter of credit pursuant to the Lease agreement totaling approximately $ 1.8

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment Information	15. Segment Information The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment. Geographic revenues for the years ended December 31, 2023 and 2022 were as follows (in thousands): Schedule of Geographic Revenues Year Ended December 31, 2023 2022 United States $ 18,199 $ 19,708 International 8,572 8,439 Total $ 26,771 $ 28,147 All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events None.

VALUATION AND QUALIFYING ACCOUN

VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
VALUATION AND QUALIFYING ACCOUNTS	VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 Balance at Beginning of Year Additions Charged to Cost and Expenses Deductions Balance at End of Year Additions Balance at Beginning of Charged to Cost and Balance at the Year Expenses Deductions End of Year Allowance for doubtful accounts and returns: Year ended December 31, 2023 $ 235 554 (117 ) $ 672 Year ended December 31, 2022 $ 180 118 (63 ) $ 235 Allowance for inventories valuation: Year ended December 31, 2023 $ 1,907 83 (51 ) $ 1,939 Year ended December 31, 2022 $ 2,165 112 (370 ) $ 1,907

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. Our investments may include, at any time, a diversified portfolio of cash equivalents and short-term and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company closely monitors events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, including Silicon Valley Bank. On March 10, 2023, Silicon Valley Bank (“SVB”), where the Company maintained accounts with a cash balance of less than 6
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand, money market instruments, and other highly liquid investments with original maturities of three months or less from the date of purchase.
Restricted Cash	Restricted Cash Restricted cash primarily consists of cash that the Company is obligated to maintain in accordance with contractual obligations.
Investments	Investments Our investments may include, at any time, a diversified portfolio of cash equivalents and short-and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. As of December 31, 2023, the Company had no Amortized cost of U.S. treasury securities and marketable debt securities are based on the Company’s purchase price adjusted for accrual of discount, or amortization of premium, and recognition of impairment charges, if any. The amortized cost of securities the Company purchases at a discount or premium will equal the face or par value at maturity or the call date, if applicable. Stated interest on investments is reported as income when earned and is adjusted for amortization or accretion of any premium or discount. Accrued interest receivable on investments, included in other current assets was less than $ 0.1 Effective January 1, 2023, the Company reports held to maturity investments net of an allowance for expected credit losses in accordance with Accounting Standards Codification Topic 326, Financial Instruments – Credit Losses (“ASC 326”). The adoption of ASC 326 had no material impact on the Company’s financial results for any prior periods, therefore no cumulative adjustment to beginning retained earnings was recorded. The Company segments its portfolio based on the underlying risk profiles of the securities and has a zero-loss expectation for U.S. treasury and U.S. government agency securities. The Company regularly reviews the securities using the probability of default method and analyzes the unrealized loss positions and evaluates the current expected credit loss by considering factors such as credit ratings, issuer-specific factors, current economic conditions, and reasonable and supportable forecasts. The Company did not have any material expected credit losses on investments or material expected credit losses on accrued interest related to investments during the years ended December 31, 2023, or December 31, 2022.
Fair Value Measurements	Fair Value Measurements Financial instruments consist of cash and cash equivalents, restricted cash, investments, accounts receivable, and accounts payable. The Company measures certain financial assets and liabilities at fair value on a recurring basis. General accounting principles for fair value measurement establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below: Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market. Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market. As of December 31, 2023, financial assets classified as Level 2 consisted of money market funds. As of December 31, 2022, financial assets classified as Level 2 consisted of money market funds, U.S. treasury securities and corporate debt securities.
Accounts Receivable and Allowance for Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts, net of allowances for expected credit losses. Credit is granted on a limited basis, with balances due generally within 30 days of billing. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Effective January 1, 2023, the Company reports accounts receivable and contract assets net of an allowance for expected credit losses in accordance with Accounting Standards Codification Topic 326, Financial Instruments – Credit Losses (“ASC 326”). The adoption of ASC 326 had no material impact on the Company’s financial results for any prior periods, therefore no cumulative adjustment to beginning retained earnings was recorded. The provision for credit loss is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. We assess collectability by reviewing the accounts receivable aging schedule on an aggregated basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectability issues. Amounts deemed uncollectible are recorded as an allowance for expected credit losses.
Inventory	Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or net realizable value. The Company periodically reviews its physical inventory and provides a reserve upon identification of potential excess or obsolete items. Excess manufacturing overhead costs attributable to idle facility expenses or abnormally low production volumes are excluded from inventory and recorded as an expense in the period incurred.
Property and Equipment	Property and Equipment Property and equipment consist primarily of leasehold improvements, construction in process, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
Long-Lived Assets	Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 3 inputs.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue and Costs of Revenue	Revenue and Costs of Revenue Revenue Recognition The Company accounts for revenue in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue from Contracts with Customers We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale of various devices as provided by co-development and co-placement arrangements, and from revenue including ongoing software updates and service contracts. We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities. For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. For arrangements with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates if necessary. Our revenue recognition policy affects the following revenue streams in our business as follows: Systems: Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation, service-type warranty, and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from service-type warranties and the implied obligation to deliver software enhancements if and when available is included in Other Recurring Revenue and is recognized ratably typically over the first year following installation of the system as the customer receives the service-type warranty and right to software updates throughout the period. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year service-type warranty or a one-year assurance-type warranty. Warranty costs for assurance-type warranty arrangements were approximately $ 0.5 0.1 33 24 Disposables: Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance-type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 24 28 Royalty: The Company receives royalties on the sale of various devices as provided by co-development and co-placement arrangements with various manufacturers. The Company was entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters, during the term of the agreement, which expired December 31, 2022. Royalty revenue from co-development and co-placement arrangements represented less than 1 7 years e Other Recurring Revenue: Other recurring revenue includes revenue from product maintenance plans, service-type warranties, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for a specified period, typically one year following installation of our systems. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 43 41 The following table summarizes the Company’s revenue for systems and disposables, service and accessories for the years ended December 31, 2023 and 2022 (in thousands): Schedule of Revenue Disaggregated by Type 2023 2022 Year Ended December 31, 2023 2022 Systems $ 8,739 $ 6,845 Disposables, service and accessories 18,032 21,302 Total revenue $ 26,771 $ 28,147 Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company’s systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $ 14.7 The following information summarizes the Company’s contract assets and liabilities (in thousands): Summary of Contract Assets and Liabilities December 31, 2023 December 31, 2022 Contract Assets - unbilled receivables $ 72 $ 539 Customer deposits $ 2,105 $ 2,339 Product shipped, revenue deferred 1,413 1,389 Deferred service and license fees 4,776 5,268 Total deferred revenue $ 8,294 $ 8,996 Less: Long-term deferred revenue (1,637 ) (1,654 ) Total current deferred revenue $ 6,657 $ 7,342 The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Customer deposits primarily relate to future system sales but can also include deposits on disposable sales. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2023 and 2022, that was included in the deferred revenue balance at the beginning of each reporting period was $ 6.1 5.9 The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets in the Company’s balance sheets $ 0.1 0.2 Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, initial training costs and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Leasing Arrangements	Leasing Arrangements A lease is defined as a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company accounts for leases in accordance with Accounting Standards Update No. 2016-02 “Leases” (Topic 842) and all subsequent ASUs that modified Topic 842 (“ASC 842”). The Company determines if an arrangement contains a lease at inception. The Company leases its facilities under operating leases. In accordance with ASC 842, operating lease agreements are recognized on the balance sheet as a right-of-use (“ROU”) asset and a corresponding lease liability. These leases generally do not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. Further, the leases do not contain contingent rent provisions. Many of our leases include both lease (i.e., fixed payments including rent, taxes, and insurance costs) and non-lease components (i.e., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. The Company’s lease agreements often include one or more options to renew at the Company’s discretion. If at lease inception, the Company considers the exercising of a renewal option to be reasonably certain, the Company will include the extended term in the calculation of the ROU asset and lease liability. The Company elected not to include short-term leases (i.e., leases with initial terms of twelve months or less) on the balance sheet. The calculated amounts of the ROU assets and lease liabilities are impacted by the length of the lease term and the discount rate used to calculate the present value of the minimum lease payments. ASC 842 requires the use of the discount rate implicit in the lease whenever this rate is readily determinable. As this rate is rarely determinable, the Company utilizes its incremental borrowing rate at lease inception.
Research and Development Costs	Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables as of December 31, 2023 or 2022, under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for its grants of stock options, non-qualified stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the stock-based compensation at the grant date and the recognition of the related expense over the period in which the stock-based compensation vests. For time-based awards, the Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The weighted average assumptions and fair value for options granted during the year ended December 31, 2023, were 1) expected dividend rate of 0 76 6.25 For market-based awards, stock-based compensation expense is recognized over the minimum service period regardless of whether or not the market target is probable of being achieved. The fair value of such awards is estimated on the grant date using Monte Carlo simulations. Shares purchased by employees under the 2022 Employee Stock Purchase Plan are considered to be non-compensatory.
Net Loss per Common Share	Net Loss per Common Share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our convertible preferred stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our convertible preferred stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our convertible preferred stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2023, the Company had 3,650,115 3.93 49,375,135 1,502,131
Income Taxes	Income Taxes In accordance with general accounting principles for income taxes ,
Product Warranty Provisions	Product Warranty Provisions The Company’s standard policy is to warrant all products against defects in material or workmanship for one year following sale or installation. Contracts related to the sale of systems typically contain a service-type warranty which is accounted for as a separate performance obligation in ASC 606, Revenue from Contracts with Customers
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Concentrations of Risk	Concentrations of Risk No single customer accounted for more than 10 10
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires enhanced income tax disclosures, primarily related to the effective tax rate reconciliation and income taxes paid. The Company does not expect a significant impact on its income tax disclosures upon adoption of the ASU which will be effective in the Company’s year ending December 31, 2025.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Revenue Disaggregated by Type	The following table summarizes the Company’s revenue for systems and disposables, service and accessories for the years ended December 31, 2023 and 2022 (in thousands): Schedule of Revenue Disaggregated by Type 2023 2022 Year Ended December 31, 2023 2022 Systems $ 8,739 $ 6,845 Disposables, service and accessories 18,032 21,302 Total revenue $ 26,771 $ 28,147
Summary of Contract Assets and Liabilities	The following information summarizes the Company’s contract assets and liabilities (in thousands): Summary of Contract Assets and Liabilities December 31, 2023 December 31, 2022 Contract Assets - unbilled receivables $ 72 $ 539 Customer deposits $ 2,105 $ 2,339 Product shipped, revenue deferred 1,413 1,389 Deferred service and license fees 4,776 5,268 Total deferred revenue $ 8,294 $ 8,996 Less: Long-term deferred revenue (1,637 ) (1,654 ) Total current deferred revenue $ 6,657 $ 7,342

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Investments, All Other Investments [Abstract]
Schedule of Cash and Cash Equivalents, Restricted Cash and Investments	The following table summarizes the Company’s cash and held to maturity securities’ amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category reported as cash and cash equivalents, restricted cash and investments as of December 31, 2023 and 2022: Schedule of Cash and Cash Equivalents, Restricted Cash and Investments December 31, 2023 Valuation Balance Sheet Classification (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Restricted Cash- current Short-term Investments Restricted Cash Cash $ 2,122 $ - $ - $ 2,122 $ 2,122 $ - $ - $ - Level 2 Money market funds 18,440 - - 18,440 17,696 525 - 219 US treasury securities - - - - - - - - Corporate debt securities - - - - - - - - Subtotal 18,440 - - 18,440 17,696 525 - 219 Total assets measured at fair value $ 20,562 $ - $ - $ 20,562 $ 19,818 $ 525 $ - $ 219 December 31, 2022 Valuation Balance Sheet Classification (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Restricted Cash- current Short-term Investments Restricted Cash Cash $ 3,258 $ - $ - $ 3,258 $ 3,258 $ - $ - $ - Level 2 Money market funds 1,615 - - 1,615 346 525 - 744 US treasury securities 14,833 2 (2 ) 14,833 4,982 - 9,851 - Corporate debt securities 9,993 - (6 ) 9,987 - - 9,993 - Subtotal 26,441 2 (8 26,435 5,328 525 19,844 744 Total assets measured at fair value $ 29,699 $ 2 $ (8 ) $ 29,693 $ 8,586 $ 525 $ 19,844 $ 744

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventory consists of the following (in thousands): Schedule of Inventories December 31, 2023 December 31, 2022 Raw materials $ 5,918 $ 6,556 Work in process 1,034 530 Finished goods 3,413 2,697 Reserve for excess and obsolescence (1,939 ) (1,907 ) Total inventory $ 8,426 $ 7,876

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Assets	Prepaid expenses and other assets consist of the following (in thousands): Schedule of Prepaid Expenses and Other Assets December 31, 2023 December 31, 2022 Prepaid expenses $ 181 $ 605 Prepaid commissions 110 187 Deposits 424 669 Other assets 98 72 Total prepaid expenses and other assets 813 1,533 Less: Noncurrent prepaid expenses and other assets (137 ) (208 ) Total current prepaid expenses and other assets $ 676 $ 1,325

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): Schedule of Property and Equipment December 31, 2023 December 31, 2022 Equipment $ 4,269 $ 4,393 Leasehold improvements 2,911 2,692 Construction in process - 204 Gross property and equipment 7,180 7,289 Less: Accumulated depreciation (3,876 ) (3,458 ) Net property and equipment $ 3,304 $ 3,831

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases
Schedule of Lease Costs and Other Lease Information	The following table represents lease costs and other lease information (in thousands): Schedule of Lease Costs and Other Lease Information 2023 2022 Year Ended December 31, 2023 2022 Operating lease cost $ 908 $ 909 Short-term lease cost 17 28 Total net lease cost $ 925 $ 937 Cash paid within operating cash flows $ 1,000 $ 1,126
Schedule of Future Minimum Operating Lease Payments	Future minimum payments for operating leases with initial or remaining terms of one year or more as of December 31, 2023, were as follows (in thousands): Schedule of Future Minimum Operating Lease Payments December 31, 2023 2024 $ 898 2025 919 2026 935 2027 956 2028 976 2029 and thereafter 3,054 Total lease payments $ 7,738 Less: Interest (2,248 ) Present value of lease liabilities $ 5,490

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities December 31, 2023 December 31, 2022 Accrued salaries, bonus, and benefits $ 1,222 $ 1,381 Accrued licenses and maintenance fees 484 484 Accrued warranties 107 163 Accrued professional services 138 129 Deferred contract obligation 1,045 1,045 Other 19 155 Total accrued liabilities 3,015 3,357 Less: Long term accrued liabilities (43 ) (51 ) Total current accrued liabilities $ 2,972 $ 3,306

Convertible Preferred Stock a_2

Convertible Preferred Stock and Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Summary of Performance Award And Market Capitalization Milestones	Summary of Performance Award And Market Capitalization Milestones Tranche # No. of Shares Subject to PSU Market Capitalization Milestones 1 1,000,000 $ 1,000,000,000 2 1,500,000 $ 1,500,000,000 3 1,500,000 $ 2,000,000,000 4 2,000,000 $ 2,500,000,000 5 1,000,000 $ 3,000,000,000 6 1,000,000 $ 3,500,000,000 7 1,000,000 $ 4,000,000,000 8 2,000,000 $ 4,500,000,000 9 1,000,000 $ 5,000,000,000 10 1,000,000 $ 5,500,000,000 Total: 13,000,000
Summary of Option and Stock Appreciation Rights Activity	Summary of Option and Stock Appreciation Rights Activity Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share Outstanding, December 31, 2022 3,208,065 $ 0.74 9.87 $ 4.21 Granted 724,000 $ 1.51 2.57 $ 2.53 Exercised (33,929 ) $ 0.74 2.03 $ 1.09 Forfeited (248,021 ) $ 0.74 9.20 $ 3.96 Outstanding, December 31, 2023 3,650,115 $ 0.74 9.87 $ 3.93
Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price	A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows: Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price Year Ended December 31, 2023 Number of Weighted Weighted Weighted Options Average Exercise Options Average Average Currently Price Per Vested Range of Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Share $ 0.00 1.00 314,887 4.16 $ 0.74 314,887 $ 0.74 $ 1.01 2.00 80,516 8.52 $ 1.57 22,771 $ 1.47 $ 2.01 4.00 1,241,853 7.12 $ 2.33 600,481 $ 2.07 $ 4.01 10.00 2,012,859 7.08 $ 5.50 1,426,027 $ 5.45 3,650,115 6.88 $ 3.93 2,364,166 $ 3.93
Summary of Restricted Stock Unit Activity	A summary of the restricted stock unit activity for the year ended December 31, 2023, is as follows: Summary of Restricted Stock Unit Activity Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit Outstanding, December 31, 2022 1,208,739 $ 4.21 Granted 610,038 $ 1.97 Vested (316,646 ) $ 1.17 Outstanding, December 31, 2023 1,502,131 $ 3.94
Summary of Reserved Shares of Common Stock for Conversion	The Company has reserved shares of common stock for conversion of convertible preferred stock, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows: Summary of Reserved Shares of Common Stock for Conversion December 31, December 31, 2023 2022 Series A Convertible Preferred Stock 54,704,831 45,023,612 Series B Convertible Preferred Stock - 5,610,121 Performance Share Unit Plan 13,000,000 13,000,000 Stock award plans 2,690,393 3,930,952 Employee Stock Purchase Plan 107,688 164,654 Reserved shares of common stock 70,502,912 67,729,339

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Provision For Income Taxes	The provision for income taxes consists of the following (in thousands): Schedule of Provision For Income Taxes 2023 2022 Year Ended December 31, 2023 2022 Deferred: Federal $ (2,108 ) $ (1,990 ) State and local (773 ) (93 ) Total deferred income tax expense (benefit) (2,881 ) (2,083 ) Valuation allowance 2,881 2,083 Income tax benefit $ — $ —
Schedule of Reconciliation of Federal Income Tax Rate	The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following: Schedule of Reconciliation of Federal Income Tax Rate 2023 2022 Year Ended December 31, 2023 2022 U.S. statutory income tax rate 21.0 % 21.0 % State and local taxes, net of federal tax benefit 1.7 % 1.1 % Stock compensation permanent differences between book and tax (7.2 )% (7.1 )% Other permanent differences between book and tax (2.4 )% (3.0 )% State rate adjustments 2.1 % (0.6 )% Other adjustments (1.3 )% - % Valuation allowance (13.9 )% (11.4 )% Effective income tax rate — % — %
Schedule of Components of Deferred Tax Asset	The components of the deferred tax asset are as follows (in thousands): Schedule of Components of Deferred Tax Asset 2023 2022 Year Ended December 31, 2023 2022 Current accruals $ 1,041 $ 859 Operating lease liabilities 1,330 1,360 Deferred revenue 68 96 Depreciation and amortization 3,172 2,007 Deferred compensation 1,570 1,525 Net operating loss carryovers 29,118 27,629 Deferred tax assets 36,299 33,476 Valuation allowance (35,066 ) (32,184 ) Net deferred tax assets before deferred tax liabilities 1,233 1,292 Operating lease right-of-use assets (1,207 ) (1,249 ) Capitalized compensation costs (26 ) (43 ) Net deferred tax assets $ - $ -

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Net loss per share attributable to common stockholders:
Schedule of Computation of Basic and Diluted Earnings Per Share	The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations (in thousands): Schedule of Computation of Basic and Diluted Earnings Per Share 2023 2022 Year Ended December 31, 2023 2022 Net loss $ (20,713 ) $ (18,292 ) Cumulative dividend on convertible preferred stock (1,343 ) (1,343 ) Net loss attributable to common stockholders $ (22,056 ) $ (19,635 ) Weighted average number of common shares and equivalents: 80,702,358 76,061,183 Basic EPS $ (0.27 ) $ (0.26 ) Diluted EPS $ (0.27 ) $ (0.26 )
Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share	The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows: Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share December 31, 2023 2022 Shares issuable upon vesting/exercise of: Options to purchase common stock 3,650,115 3,208,065 Series A Convertible Preferred Stock and Accumulated Dividends 49,375,135 47,364,216 Series B Convertible Preferred Stock - 5,610,121 Restricted stock units 1,502,131 1,208,739 54,527,381 57,391,141

Product Warranty Provisions (Ta

Product Warranty Provisions (Tables)	12 Months Ended
	Dec. 31, 2023
Guarantees and Product Warranties [Abstract]
Schedule of Accrued Warranty	Accrued warranty, which is included in other accrued liabilities, consists of the following (in thousands): Schedule of Accrued Warranty December 31, 2023 December 31, 2022 Warranty accrual, beginning of the fiscal period $ 163 $ 242 Accrual adjustment for product warranty 547 113 Payments made (603 ) (192 ) Warranty accrual, end of the fiscal period $ 107 $ 163

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Schedule of Geographic Revenues	Schedule of Geographic Revenues Year Ended December 31, 2023 2022 United States $ 18,199 $ 19,708 International 8,572 8,439 Total $ 26,771 $ 28,147

Schedule of Revenue Disaggregat

Schedule of Revenue Disaggregated by Type (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Total revenue	$ 26,771	$ 28,147
Systems [Member]
Product Information [Line Items]
Total revenue	8,739	6,845
Disposables Service and Accessories [Member]
Product Information [Line Items]
Total revenue	$ 18,032	$ 21,302

Summary of Contract Assets and

Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Contract Assets - unbilled receivables	$ 72	$ 539
Total deferred revenue	8,294	8,996
Less: Long-term deferred revenue	(1,637)	(1,654)
Total current deferred revenue	6,657	7,342
Customer Deposits [Member]
Product Information [Line Items]
Total deferred revenue	2,105	2,339
Product Shipped Revenue Deferred [Member]
Product Information [Line Items]
Total deferred revenue	1,413	1,389
Deferred Service And License Fees [Member]
Product Information [Line Items]
Total deferred revenue	$ 4,776	$ 5,268

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 10, 2023
Product Information [Line Items]
Minimum cash balance percentage			6%
Short-term investments		$ 19,844
Remaining performance obligations	14,700
Contract with customer liability revenue recognized	6,100	5,900
Capitalized contract cost	$ 100	$ 200
Expected dividend rate	0%
Expected volatility	76%
Expected term	6 years 3 months
Potential common shares excluded from diluted earnings per share	54,527,381	57,391,141
Series A Convertible Preferred Stock [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	49,375,135
Stock Options and Stock Appreciation Rights [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	3,650,115
Weighted average exercise price	$ 3.93
Restricted Stock [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	1,502,131
Revenue From System Delivery and Installation [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	33%	24%
Disposable revenue [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	24%	28%
Royalty Revenue [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	1%	7%
Other recurring Revenue [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	43%	41%
Systems [Member]
Product Information [Line Items]
Warranty costs	$ 500	$ 100
Maximum [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Single Country Other Than the US [Member]
Product Information [Line Items]
Concentration risk percentage	10%	10%
Maximum [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Single Customer [Member]
Product Information [Line Items]
Concentration risk percentage	10%	10%
Other Current Assets [Member] | Maximum [Member]
Product Information [Line Items]
Accrued interest receivable on investments	$ 100	$ 100

Schedule of Cash and Cash Equiv

Schedule of Cash and Cash Equivalents, Restricted Cash and Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Cash and Cash Equivalents	$ 19,818	$ 8,586
Restricted Cash- current	525	525
Short-term Investments		19,844
Restricted Cash	219	744
Total assets measured at fair value, Amortized Cost	20,562	29,699
Total assets measured at fair value, Gross Unrealized Gains		2
Total assets measured at fair value, Gross Unrealized Losses		(8)
Total assets measured at fair value, Fair value	20,562	29,693
Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Cash and Cash Equivalents	17,696	5,328
Restricted Cash- current	525	525
Short-term Investments		19,844
Restricted Cash	219	744
Cash and Held to maturity securities, Amortized Cost	18,440	26,441
Cash and Held to maturity securities, Gross Unrealized Gains		2
Cash and Held to maturity securities, Gross Unrealized Losses		(8)
Cash and Held to maturity securities, Fair Value	18,440	26,435
Cash [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Cash, Amortized Cost	2,122	3,258
Cash, Gross Unrealized Gains
Cash, Gross Unrealized Losses
Cash, Fair Value	2,122	3,258
Cash and Cash Equivalents	2,122	3,258
Restricted Cash- current
Short-term Investments
Restricted Cash
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Cash, Amortized Cost	18,440	1,615
Cash, Gross Unrealized Gains
Cash, Gross Unrealized Losses
Cash, Fair Value	18,440	1,615
Cash and Cash Equivalents	17,696	346
Restricted Cash- current	525	525
Short-term Investments
Restricted Cash	219	744
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Cash and Cash Equivalents		4,982
Restricted Cash- current
Short-term Investments		9,851
Restricted Cash
Cash and Held to maturity securities, Amortized Cost		14,833
Cash and Held to maturity securities, Gross Unrealized Gains		2
Cash and Held to maturity securities, Gross Unrealized Losses		(2)
Cash and Held to maturity securities, Fair Value		14,833
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Cash and Cash Equivalents
Restricted Cash- current
Short-term Investments		9,993
Restricted Cash
Cash and Held to maturity securities, Amortized Cost		9,993
Cash and Held to maturity securities, Gross Unrealized Gains
Cash and Held to maturity securities, Gross Unrealized Losses		(6)
Cash and Held to maturity securities, Fair Value		$ 9,987

Financial Instruments (Details

Financial Instruments (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Interest income	$ 1,096	$ 484

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 5,918	$ 6,556
Work in process	1,034	530
Finished goods	3,413	2,697
Reserve for excess and obsolescence	(1,939)	(1,907)
Total inventory	$ 8,426	$ 7,876

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 181	$ 605
Prepaid commissions	110	187
Deposits	424	669
Other assets	98	72
Total prepaid expenses and other assets	813	1,533
Less: Noncurrent prepaid expenses and other assets	(137)	(208)
Total current prepaid expenses and other assets	$ 676	$ 1,325

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 7,180	$ 7,289
Less: Accumulated depreciation	(3,876)	(3,458)
Net property and equipment	3,304	3,831
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	4,269	4,393
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	2,911	2,692
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment		$ 204

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Disposals of fixed assets	$ 0.2	$ 0.2
Property and equipment additions	$ 0.1	$ 1.2

Schedule of Lease Costs and Oth

Schedule of Lease Costs and Other Lease Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases
Operating lease cost	$ 908	$ 909
Short-term lease cost	17	28
Total net lease cost	925	937
Cash paid within operating cash flows	$ 1,000	$ 1,126

Schedule of Future Minimum Oper

Schedule of Future Minimum Operating Lease Payments (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Leases
2024	$ 898
2025	919
2026	935
2027	956
2028	976
2029 and thereafter	3,054
Total lease payments	7,738
Less: Interest	(2,248)
Present value of lease liabilities	$ 5,490

Leases (Details Narrative)

Leases (Details Narrative) $ in Millions	Mar. 01, 2021 USD ($) ft²	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average discount rate, operating lease		9%
Weighted average remaining lease term, operating lease		7 years 11 months 26 days
Office Lease Agreement [Member] | Globe Building Company [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²	43,100
Operating lease, term	10 years
Operating lease, option to extend	two
Operating lease, renewal term	5 years
Office Lease Agreement [Member] | Globe Building Company [Member] | 2022 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent	$ 0.8
Office Lease Agreement [Member] | Globe Building Company [Member] | 2031 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent	$ 1

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued salaries, bonus, and benefits	$ 1,222	$ 1,381
Accrued licenses and maintenance fees	484	484
Accrued warranties	107	163	$ 242
Accrued professional services	138	129
Deferred contract obligation	1,045	1,045
Other	19	155
Total accrued liabilities	3,015	3,357
Less: Long term accrued liabilities	(43)	(51)
Total current accrued liabilities	$ 2,972	$ 3,306

Summary of Performance Award An

Summary of Performance Award And Market Capitalization Milestones (Details) - PSU Agreement [Member] - Mr. Fischel [Member]	Feb. 23, 2021 USD ($) shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	13,000,000
Market capitalization milestone, amount | $	$ 1,000,000,000
Share-Based Payment Arrangement, Tranche One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 1,000,000,000
Share-Based Payment Arrangement, Tranche Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,500,000
Market capitalization milestone, amount | $	$ 1,500,000,000
Share-Based Payment Arrangement, Tranche Three [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,500,000
Market capitalization milestone, amount | $	$ 2,000,000,000
ShareBased Compensation Award Tranche Four [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	2,000,000
Market capitalization milestone, amount | $	$ 2,500,000,000
ShareBased Compensation Award Tranche Five [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 3,000,000,000
ShareBased Compensation Award Tranche Six [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 3,500,000,000
ShareBased Compensation Award Tranche Seven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 4,000,000,000
ShareBased Compensation Award Tranche Eight [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	2,000,000
Market capitalization milestone, amount | $	$ 4,500,000,000
ShareBased Compensation Award Tranche Nine [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 5,000,000,000
ShareBased Compensation Award Tranche Ten [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 5,500,000,000

Summary of Option and Stock App

Summary of Option and Stock Appreciation Rights Activity (Details) - Equity Option [Member] - Stock Appreciation Rights (SARs) [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Number of Options/SARs, Outstanding, Beginning | shares	3,208,065
Weighted Average Exercise Price per Share, Outstanding, Beginning	$ 4.21
Number of Options/SARs, Granted | shares	724,000
Weighted Average Exercise Price per Share, Granted	$ 2.53
Number of Options/SARs, Exercised | shares	(33,929)
Weighted Average Exercise Price per Share, Exercised	$ 1.09
Number of Options/SARs, Forfeited | shares	(248,021)
Weighted Average Exercise Price per Share, Forfeited	$ 3.96
Number of Options/SARs, Outstanding, Ending | shares	3,650,115
Weighted Average Exercise Price per Share, Outstanding, Ending	$ 3.93
Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Range of Exercise Price, Outstanding, Beginning	0.74
Range of Exercise Price, Granted	1.51
Range of Exercise Price, Exercised	0.74
Range of Exercise Price, Forfeited	0.74
Range of Exercise Price, Outstanding, Ending	0.74
Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Range of Exercise Price, Outstanding, Beginning	9.87
Range of Exercise Price, Granted	2.57
Range of Exercise Price, Exercised	2.03
Range of Exercise Price, Forfeited	9.20
Range of Exercise Price, Outstanding, Ending	$ 9.87

Summary of Option and Stock A_2

Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price (Details) - Stock Option and Stock Appreciation Rights (SARs) [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options Outstanding | shares	3,650,115
Weighted Average Remaining Life	6 years 10 months 17 days
Weighted Average Exercise Price	$ 3.93
Number of Options Currently Exercisable | shares	2,364,166
Weighted Average Exercise Price per Vested Share	$ 3.93
Range of Exercise Prices One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	0
Range of Exercise Prices, Upper Limit	$ 1
Options Outstanding | shares	314,887
Weighted Average Remaining Life	4 years 1 month 28 days
Weighted Average Exercise Price	$ 0.74
Number of Options Currently Exercisable | shares	314,887
Weighted Average Exercise Price per Vested Share	$ 0.74
Range of Exercise Prices Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	1.01
Range of Exercise Prices, Upper Limit	$ 2
Options Outstanding | shares	80,516
Weighted Average Remaining Life	8 years 6 months 7 days
Weighted Average Exercise Price	$ 1.57
Number of Options Currently Exercisable | shares	22,771
Weighted Average Exercise Price per Vested Share	$ 1.47
Range of Exercise Prices Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	2.01
Range of Exercise Prices, Upper Limit	$ 4
Options Outstanding | shares	1,241,853
Weighted Average Remaining Life	7 years 1 month 13 days
Weighted Average Exercise Price	$ 2.33
Number of Options Currently Exercisable | shares	600,481
Weighted Average Exercise Price per Vested Share	$ 2.07
Range of Exercise Prices Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	4.01
Range of Exercise Prices, Upper Limit	$ 10
Options Outstanding | shares	2,012,859
Weighted Average Remaining Life	7 years 29 days
Weighted Average Exercise Price	$ 5.50
Number of Options Currently Exercisable | shares	1,426,027
Weighted Average Exercise Price per Vested Share	$ 5.45

Summary of Restricted Stock Uni

Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, Beginning | shares	1,208,739
Weighted Average Grant Date Fair Value per Unit, Outstanding, Beginning | $ / shares	$ 4.21
Number of Restricted Stock Units, Outstanding, Granted | shares	610,038
Weighted Average Grant Date Fair Value per Unit, Granted | $ / shares	$ 1.97
Number of Restricted Stock Units, Outstanding, Vested | shares	(316,646)
Weighted Average Grant Date Fair Value per Unit, Vested | $ / shares	$ 1.17
Number of Restricted Stock Units, Outstanding, Ending | shares	1,502,131
Weighted Average Grant Date Fair Value per Unit, Outstanding, Ending | $ / shares	$ 3.94

Summary of Reserved Shares of C

Summary of Reserved Shares of Common Stock for Conversion (Details) - shares	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Reserved shares of common stock	70,502,912	67,729,339
Performance Share Unit Plan [Member]
Class of Stock [Line Items]
Reserved shares of common stock	13,000,000	13,000,000
Stock Award Plans [Member]
Class of Stock [Line Items]
Reserved shares of common stock	2,690,393	3,930,952
Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Reserved shares of common stock	107,688	164,654
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Reserved shares of common stock	54,704,831	45,023,612
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Reserved shares of common stock		5,610,121

Convertible Preferred Stock a_3

Convertible Preferred Stock and Stockholders’ Equity (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Feb. 23, 2021	Sep. 30, 2016	Dec. 31, 2023	Dec. 31, 2022	Sep. 29, 2021	Aug. 07, 2019	Mar. 05, 2018	Feb. 28, 2018
Class of Stock [Line Items]
Common stock, voting rights			The holders of common stock are entitled to one vote for each share held
Payments of dividends common stock			$ 0
Reserved shares of common stock			70,502,912	67,729,339
Preferred stock, par value			$ 0.001	$ 0.001
Stock-based compensation expense			$ 10,623,000	$ 10,576,000
Unrecognized stock-based compensation expense			$ 3,200,000
Share based payment arrangement, cost not yet recognized, period			4 years
Options number of shares vested				881,207
Fair value of shares purchase			$ 96,000	$ 118,000
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of shares granted			610,038
2012 Stock Incentive Plan [Member]
Class of Stock [Line Items]
Stock plan expiration date			May 19, 2022
Stock Award Plans [Member]
Class of Stock [Line Items]
Reserved shares of common stock			2,690,393	3,930,952
2022 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Share vesting description			The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years.
Share vesting percentage			25%
Share-based compensation arrangement by share-based payment award, award vesting period			3 years
2022 Stock Incentive Plan [Member] | Stock Appreciation Rights (SARs) [Member]
Class of Stock [Line Items]
Share vesting description			Stock appreciation rights granted under the 2022 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant.
Share-based compensation arrangement by share-based payment award, expiration period			10 years
Share vesting percentage			25%
Share-based compensation arrangement by share-based payment award, award vesting period			3 years
2022 Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period			4 years
Share price			$ 1.75	$ 2.07
Aggregate intrinsic value, outstanding			$ 2,600,000	$ 2,500,000
Aggregate intrinsic value, vested			$ 600,000
2022 Stock Incentive Plan [Member] | Stock Options and Stock Appreciation Rights (SARs) [Member]
Class of Stock [Line Items]
Contractual term			6 years 10 months 17 days
Number of options and stock appreciation rights outstanding			3,650,115
Number of options and stock appreciation rights, Exercisable, Number			2,364,166
Number of options and stock appreciation rights, weighted average exercise price			$ 3.93
Number of options and stock appreciation rights remaining contractual term			6 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			$ 300,000	$ 500,000
Share price			$ 1.75	$ 2.07
Options number of shares vested			337,408
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 100,000	$ 100,000
2012 Stock Incentive Plan [Member] | Stock Options and Stock Appreciation Rights (SARs) [Member]
Class of Stock [Line Items]
Options grants weighted average grant date fair value			$ 2.53	$ 4.49
2022 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Reserved shares of common stock			107,688
Maximum purchase percentage of employees compensation			15%
Maximum fair value percentage of shares subject to repurchase obligation			95%
Maximum [Member] | 2022 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Fair value of shares purchase			$ 25,000
Employees Directors And Third Party Consultants [Member] | 2022 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Share-based compensation arrangement by share-based payment award, expiration period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent			100%
PSU Agreement [Member] | Mr. Fischel [Member]
Class of Stock [Line Items]
Performance award term	10 years
Number of shares granted	13,000,000
Maximum market capitalization milestone, amount	$ 1,000,000,000
Increase in market capitalization milestone, amount	$ 500,000,000
Share vesting description	Each tranche represents a portion of the PSUs covering the number of shares outlined in the table above. Each tranche vests upon (i) satisfaction of the market capitalization milestones and (ii) continued employment as CEO of the Company from the grant date through December 31, 2030. Absent an earlier termination, the PSUs will expire on December 31, 2030. If our CEO ceases employment as CEO of the Company for any reason including death, disability, termination for cause or without cause (as defined in the award agreement), or if he voluntary terminates after service as CEO for at least five years, the remaining service period will be waived and he will retain any PSUs that have vested through the date of termination.
Stock-based compensation expense			$ 7,100,000	$ 7,100,000
Unrecognized stock-based compensation expense			$ 37,000,000	$ 44,100,000
PSU Agreement [Member] | Mr. Fischel [Member] | Maximum [Member]
Class of Stock [Line Items]
Maximum market capitalization milestone, amount	$ 5,500,000,000
Warrant [Member]
Class of Stock [Line Items]
Unexercised warrants					15,385
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Reserved shares of common stock				5,610,121
Series B Convertible Preferred Stock [Member] | Private Placement [Member]
Class of Stock [Line Items]
Preferred stock, par value						$ 0.001
Preferred stock, convertible, conversion price						$ 2.05
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Reserved shares of common stock			54,704,831	45,023,612
Preferred stock, par value		$ 0.001
Sale of stock, number of shares sold		24,000
Preferred stock, stated value		$ 1,000
Redemption price per share		$ 0.65					$ 0.28	$ 0.70
Common stock issuable from warrants		36,923,078
Preferred stock dividend rate		6%
Preferred stock redemption, triggering event, percent of common stock sold threshold		50%

Schedule of Provision For Incom

Schedule of Provision For Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal	$ (2,108)	$ (1,990)
State and local	(773)	(93)
Total deferred income tax expense (benefit)	(2,881)	(2,083)
Valuation allowance	2,881	2,083
Income tax benefit

Schedule of Reconciliation of F

Schedule of Reconciliation of Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	21%	21%
State and local taxes, net of federal tax benefit	1.70%	1.10%
Stock compensation permanent differences between book and tax	(7.20%)	(7.10%)
Other permanent differences between book and tax	(2.40%)	(3.00%)
State rate adjustments	2.10%	(0.60%)
Other adjustments	(1.30%)
Valuation allowance	(13.90%)	(11.40%)
Effective income tax rate

Schedule of Components of Defer

Schedule of Components of Deferred Tax Asset (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Current accruals	$ 1,041	$ 859
Operating lease liabilities	1,330	1,360
Deferred revenue	68	96
Depreciation and amortization	3,172	2,007
Deferred compensation	1,570	1,525
Net operating loss carryovers	29,118	27,629
Deferred tax assets	36,299	33,476
Valuation allowance	(35,066)	(32,184)
Net deferred tax assets before deferred tax liabilities	1,233	1,292
Operating lease right-of-use assets	(1,207)	(1,249)
Capitalized compensation costs	(26)	(43)
Net deferred tax assets

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Employee benefits and share-based compensation	$ 7.1	$ 7.1
Percentage of valuation allowance of deferred tax assets	100%
Federal net operating losses carryforwards	$ 127.4
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Reserves for uncertain tax positions	0.1	0.1
Accrued interest and penalties	0.1	$ 0.1
Prior to 2018 Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Federal net operating losses carryforwards	$ 98.8
Operating loss carryforwards limitations on use	expire between 2030 and 2037
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 213.7
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 40.2
Operating loss carryforwards limitations on use	expire at various dates between 2024 and 2042 if not utilized
Number of prior years subject to examination	10 years

Schedule of Computation of Basi

Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Net loss per share attributable to common stockholders:
Net loss	$ (20,713)	$ (18,292)
Cumulative dividend on convertible preferred stock	(1,343)	(1,343)
Net loss attributable to common stockholders	$ (22,056)	$ (19,635)
Weighted average number of common shares and equivalents - Basic	80,702,358	76,061,183
Weighted average number of common shares and equivalents - Diluted	80,702,358	76,061,183
Basic EPS	$ (0.27)	$ (0.26)
Diluted EPS	$ (0.27)	$ (0.26)

Schedule of Anti-Dilutive Secur

Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	54,527,381	57,391,141
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	3,650,115	3,208,065
Series A Convertible Preferred Stock and Accumulated Dividends [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	49,375,135	47,364,216
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share		5,610,121
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	1,502,131	1,208,739

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, cost	$ 0.3	$ 0.3
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Percentage of employee contributions participating employee's compensation	3%

Schedule of Accrued Warranty (D

Schedule of Accrued Warranty (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Guarantees and Product Warranties [Abstract]
Warranty accrual, beginning of the fiscal period	$ 163	$ 242
Accrual adjustment for product warranty	547	113
Payments made	(603)	(192)
Warranty accrual, end of the fiscal period	$ 107	$ 163

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Millions	Dec. 31, 2023	Apr. 30, 2021
Line of Credit Facility [Line Items]
Underlying inventory	$ 0.6
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Long-term line of credit		$ 1.8

Schedule of Geographic Revenues

Schedule of Geographic Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total	$ 26,771	$ 28,147
Operating Segments [Member] | UNITED STATES
Segment Reporting Information [Line Items]
Total	18,199	19,708
Operating Segments [Member] | Non-US [Member]
Segment Reporting Information [Line Items]
Total	$ 8,572	$ 8,439

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
SEC Schedule, 12-09, Allowance, Credit Loss [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance	$ 235	$ 180
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense	554	118
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction	(117)	(63)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	672	235
SEC Schedule, 12-09, Reserve, Inventory [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance	1,907	2,165
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense	83	112
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction	(51)	(370)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	$ 1,939	$ 1,907